Kura Oncology (KURA) vs. Its Rivals Head to Head Survey
Kura Oncology (NASDAQ: KURA) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Kura Oncology to related companies based on the strength of its institutional ownership, earnings, analyst recommendations, risk, valuation, dividends and profitability.
Valuation and Earnings
This table compares Kura Oncology and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Kura Oncology||N/A||-$27.56 million||-8.81|
|Kura Oncology Competitors||$284.49 million||$33.78 million||82.35|
This table compares Kura Oncology and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kura Oncology Competitors||-5,309.53%||-218.50%||-39.43%|
Volatility & Risk
Kura Oncology has a beta of 4.87, suggesting that its stock price is 387% more volatile than the S&P 500. Comparatively, Kura Oncology’s competitors have a beta of 6.02, suggesting that their average stock price is 502% more volatile than the S&P 500.
Insider & Institutional Ownership
64.3% of Kura Oncology shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 21.8% of Kura Oncology shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a breakdown of current ratings and recommmendations for Kura Oncology and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kura Oncology Competitors||866||3223||11692||232||2.71|
Kura Oncology presently has a consensus price target of $18.13, indicating a potential upside of 32.78%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.84%. Given Kura Oncology’s competitors higher probable upside, analysts clearly believe Kura Oncology has less favorable growth aspects than its competitors.
About Kura Oncology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.